Best Blincyto (Blinatumomab) Medicine in India

Blincyto (Blinatumomab) is a targeted anticancer treatment used for certain types of B-cell precursor acute lymphoblastic leukemia (B-ALL). It is a bispecific T-cell engager (BiTE) therapy that helps the body's immune system recognize and destroy abnormal leukemia cells, supporting cancer control and reducing the number of leukemia cells.

Blincyto (Blinatumomab) is administered by a healthcare professional through an intravenous infusion according to a specific treatment schedule. The dose and duration are determined by your doctor based on your condition, treatment history, and response to therapy. Regular blood tests and medical monitoring may be required throughout treatment to check your response and manage potential side effects.

Common side effects of Blincyto (Blinatumomab) may include fever, headache, nausea, fatigue, infections, low blood cell counts, and infusion-related reactions. Serious reactions involving the nervous system or immune system can also occur and require prompt medical attention. Inform your doctor about your medical history and all medicines or supplements you are taking before starting treatment.

Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL)

Blincyto (Blinatumomab) is used to treat certain forms of B-cell precursor acute lymphoblastic leukemia (B-ALL). It helps the immune system identify and destroy abnormal B-cells by bringing T-cells into close contact with leukemia cells. This can reduce the number of leukemia cells and help control the progression of the disease.

Some side effects of Blincyto (Blinatumomab) may improve as your body adjusts to the treatment. Consult your doctor if any side effect persists, becomes severe, or causes concern.

Common Side Effects of Blincyto (Blinatumomab)

Blincyto (Blinatumomab) is administered by a healthcare professional through a continuous intravenous infusion. The dose and treatment schedule are determined by your doctor based on your condition, treatment response, and overall health. Regular blood tests and medical monitoring may be required during treatment. Do not change or stop the treatment schedule without your doctor's advice.

Blincyto (Blinatumomab) works by connecting T-cells of the immune system with CD19-positive B-cells, including abnormal leukemia cells. This brings the immune cells close to the cancer cells and activates T-cells to destroy them. By helping the immune system target leukemia cells, Blinatumomab can reduce cancer cell levels and help control the progression of B-cell precursor acute lymphoblastic leukemia (B-ALL).

• Keep the unopened vial refrigerated between 2°C and 8°C.
• Do not allow the vial or prepared infusion bag to freeze.
• Store the product in its original carton to shield it from light exposure.
• Once prepared, the infusion bag can be stored for up to 96 hours under refrigeration or up to 48 hours at room temperature.

Alcohol CONSULT YOUR DOCTOR

Consult your doctor before consuming alcohol during treatment with Blincyto (Blinatumomab).

Pregnancy CONSULT YOUR DOCTOR

Blincyto (Blinatumomab) may harm an unborn baby. Inform your doctor if you are pregnant or planning to become pregnant.

Breastfeeding CONSULT YOUR DOCTOR

Consult your doctor before breastfeeding during treatment with Blincyto (Blinatumomab).

Driving CONSULT YOUR DOCTOR

Blincyto (Blinatumomab) may cause dizziness, confusion, or nervous system effects. Avoid driving if you experience these symptoms.

Kidney CAUTION

Inform your doctor if you have kidney problems. Your condition may require careful monitoring during treatment.

Liver CAUTION

Tell your doctor about any liver problems before starting treatment. Liver function may be monitored during therapy.

• Attend all scheduled medical appointments and blood tests so your doctor can monitor your blood counts, liver function, and treatment response.
• Report fever, chills, unusual tiredness, or other signs of infection promptly, as Blincyto (Blinatumomab) may lower blood cell counts.
• Contact your doctor immediately if you experience confusion, dizziness, seizures, difficulty speaking, loss of balance, or other nervous system changes.
• Inform your doctor about all medicines, vitamins, herbal products, and dietary supplements you are taking to help prevent possible interactions.
• Do not change, interrupt, or stop Blincyto (Blinatumomab) treatment without your doctor's advice.
• Read More About - Blincyto (Blinatumomab) from Pharma Five.

Pharma Five, can help patients facilitate the import of Blincyto (Blinatumomab) in small quantities for personal use. For this purpose, the applicant needs to submit an application in Form 12A, accompanied by a prescription issued by a Registered Medical Practitioner (RMP).

With extensive experience in the pharmaceutical sector, Pharma Five helps patients seeking Blincyto (Blinatumomab) by providing professional guidance and facilitation for accessing specialized medicines. Pharma Five provides extensive pharmaceutical service coverage across India, serving patients and healthcare requirements in prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.